20/20 Biolabs, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALZNAlzamend Neuro, Inc. | $1.66 | — | 9.7x | — | -373.18% | $8.01M |
| ICCMIceCure Medical Ltd. | $2.30 | — | 0.7x | — | -228.31% | $7.88M |
| TRIBTrinity Biotech PLC | $9.68 | — | — | — | — | $7.87M |
| CUPRCuprina Holdings (Cayman) LTD | $3.01 |
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Company description provided by Yahoo Finance.
| — |
| 2.0x |
| — |
| -1569.06% |
| $8.07M |
| CNSPCNS Pharmaceuticals, Inc. | $5.52 | — | 0.4x | — | -106.62% | $8.07M |
| AIMAIM ImmunoTech Inc. | $0.26 | — | 1.0x | — | -2382.30% | $7.87M |